Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
10 February 2023Website:
http://mineralystx.comNext earnings report:
07 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 01 Jul 2024 20:02:56 GMTDividend
Analysts recommendations
Institutional Ownership
MLYS Latest News
Dr. Olivier Litzka has resigned from the Board, effective June 13, 2024 Dr. Olivier Litzka has resigned from the Board, effective June 13, 2024
Mineralys Therapeutics, Inc. (MLYS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Mineralys Therapeutics Inc. (NASDAQ:MLYS ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Dan Ferry - LifeSci Advisors Jon Congleton - Chief Executive Officer Adam Levy - Chief Financial Officer and Chief Business Officer David Rodman - Chief Medical Officer Conference Call Participants Michael DiFiore - Evercore ISI Greg Harrison - Bank of America Jack Padovano - Stifel Seamus Fernandez - Guggenheim Securities Mohit Bansal - Wells Fargo Operator Good afternoon, ladies and gentlemen, and welcome to the Mineralys Therapeutics Third Quarter 2023 Conference Call. [Operator Instructions].
The mean of analysts' price targets for Mineralys Therapeutics, Inc. (MLYS) points to a 199.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Mineralys Therapeutics, Inc. (MLYS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q2 2023 Results Conference Call August 7, 2023 4:30 PM ET Company Participants Dan Ferry - LifeSci Advisors Jon Congleton - Chief Executive Officer Adam Levy - Chief Financial Officer and Chief Business Officer David Rodman - Chief Medical Officer Conference Call Participants Michael DiFiore - Evercore Greg Harrison - Bank of America Mohit Bansal - Wells Fargo Rich Law - Credit Suisse Operator Greetings, and welcome to the Mineralys Second Quarter 2023 Earnings Call [Operator Instructions]. As a reminder, this conference is being recorded.
RADNOR, Pa., July 31, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced it will report its financial results from the second quarter ended June 30, 2023, after the financial markets close on Monday, August 7, 2023.
What type of business is Mineralys Therapeutics?
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
What sector is Mineralys Therapeutics in?
Mineralys Therapeutics is in the Healthcare sector
What industry is Mineralys Therapeutics in?
Mineralys Therapeutics is in the Biotechnology industry
What country is Mineralys Therapeutics from?
Mineralys Therapeutics is headquartered in United States
When did Mineralys Therapeutics go public?
Mineralys Therapeutics initial public offering (IPO) was on 10 February 2023
What is Mineralys Therapeutics website?
https://mineralystx.com
Is Mineralys Therapeutics in the S&P 500?
No, Mineralys Therapeutics is not included in the S&P 500 index
Is Mineralys Therapeutics in the NASDAQ 100?
No, Mineralys Therapeutics is not included in the NASDAQ 100 index
Is Mineralys Therapeutics in the Dow Jones?
No, Mineralys Therapeutics is not included in the Dow Jones index
When does Mineralys Therapeutics report earnings?
The next expected earnings date for Mineralys Therapeutics is 07 August 2024